Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
about
Placebos without deception: a randomized controlled trial in irritable bowel syndromeCatechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndromeComponents of placebo effect: randomised controlled trial in patients with irritable bowel syndromeDiagnosis and treatment of diarrhea-predominant irritable bowel syndromeIncidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship.Patient and practitioner influences on the placebo effect in irritable bowel syndromeRecent advances in pharmacological treatment of irritable bowel syndrome.Predictors of patient-assessed illness severity in irritable bowel syndrome.The treatment of irritable bowel syndromeOptimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.The placebo effect in irritable bowel syndrome trials: a meta-analysis.Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.Role of serotonin in the pathophysiology of the irritable bowel syndrome.Novel therapies in the treatment of irritable bowel syndrome.Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome.Evaluation of drug treatment in irritable bowel syndrome.Evidence-based clinical practice guidelines for irritable bowel syndrome.Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patientsDiagnosis and therapy of irritable bowel syndrome.An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium.Review article: epidemiology and quality of life in functional gastrointestinal disorders.Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.Targeted therapies for diarrhea-predominant irritable bowel syndrome.Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trialsEmerging drugs for irritable bowel syndrome.Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease.Mechanisms of hypersensitivity in IBS and functional disorders.Serotonin receptor modulators in the treatment of irritable bowel syndrome.Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders.Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.New treatments for irritable bowel syndrome in womenNeural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot studyThe trials and tribulations of drug development for functional gastrointestinal disorders.
P2860
Q21091076-BEAEBA0F-7D16-454A-BEEE-D473B0DF7806Q21133920-AE2742AF-447E-4B7B-8D80-AB5A9E7FA6E3Q24647883-962C08E1-A882-4266-9A01-67AAE5545186Q26765272-8490ADCF-AB6D-4638-80FD-CE0C9F641614Q31036400-7009DEE8-62B7-40AA-A570-798E881BEF28Q33451900-EACAD01C-F18F-4ED9-A95C-1E2F4F29F15BQ33624179-142BE456-4238-4899-A817-BC14B2CC4E26Q33636363-F16D93C7-15BD-467C-B01C-2DB361018AE8Q33958853-6DC00FC9-1C0A-48AA-B8DC-7CBF7DC2CAE6Q34170665-87B70D56-903C-4803-80AF-5999CC66470BQ34409009-DFC03657-210E-4964-B537-347A736A96D7Q34409173-0B474384-FED3-4769-A009-5A41747966EFQ34421382-092CA4CF-95FB-4797-BDBA-BDF58331E316Q34552742-00360CE1-C062-4942-B29A-5FE0B08F960AQ35047066-E61DAFA0-F198-4993-9FD6-150A6DD9CAF4Q35094684-9A8131A3-DF1F-4B03-8F09-B2A04EF71B02Q35129532-221D4532-E225-4C0F-A2A6-186E5E5BE721Q35216829-4ACFB564-0042-4404-A887-65AC42FF39E4Q35513973-EB1922DB-B609-4942-83B3-35A190954B8EQ35760855-4B70E09F-4119-4306-943A-764A20D62A86Q35873847-3263DB08-6BC5-4817-8C90-9D5B39BE908BQ35917169-9A32693A-146B-4FB5-8C23-09AACF95D566Q35936950-25846774-3D14-4358-9195-06E91A874412Q35985391-60B792D4-F373-4B9E-95EA-AD1D60DFD6BDQ36065945-2C6592EA-F49B-40EF-8C96-F9313DB05D4AQ36072575-983D7359-89A5-413B-9CD9-C99F01E75DDFQ36297736-7898E3BD-BF8A-4449-8F8E-CDD8CC87A752Q36307366-D7548368-64BF-44FD-9C9A-6EFDF184BB88Q36458417-8D1EC04C-8F88-4823-903C-9804BBF56D7DQ36536707-9A9DE4ED-2AEB-4A97-977F-4199FFA3ED78Q36536709-6DC1145D-04A1-4639-BCF0-859F459147ACQ36583822-E1847A20-E740-4FBD-9E2F-44D59B9A5FD1Q36728934-37C59551-D3EA-4724-9A24-DE8D00A725B2Q36822923-A9B439E2-C4AE-47B8-831F-04C8E4A44695Q36874388-9C81615C-AE98-47E6-8099-A21CA4CF2FE0Q36983944-806602B5-6F8D-4722-AC0B-EA2A364D0511Q36998938-7C1E9AA3-06B5-49AD-8574-B3572F9B4380Q37120300-60F19E35-9CEE-44EB-A1F4-D905BA2E4171Q37130193-836433D6-6B72-4793-B1E9-5E10B567C9FFQ37134572-C9327FDE-B19B-4DFC-A801-340E3E5D4AA1
P2860
Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@en
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@nl
type
label
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@en
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@nl
prefLabel
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@en
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@nl
P2093
P2860
P1476
Alosetron controls bowel urgen ...... nant irritable bowel syndrome.
@en
P2093
Lotronex Investigator Team
P Jhingran
R A Wright
P2860
P304
P356
10.1111/J.1572-0241.2001.04128.X
P407
P577
2001-09-01T00:00:00Z